Form 8K Actinium Pharmaceuticals Inc For: 14 August
- Investing.com
- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Actinium Pharmaceuticals Inc (ATNM)
Track today's live Actinium Pharmaceuticals (ATNM) share price, performance and key data on this page with our current NYSE:ATNM stock exchange information. Analyse interactive charts and historical data, check technical buy and sell signals in real time, and follow the Actinium Pharmaceuticals share price on the NYSE exchange. Use the dropdown to switch exchange for the ATNM share price, head to our technical summary section, which provides analysis on Actinium Pharmaceuticals share price buy/sell indicators using real-time data (or discuss the Actinium Pharmaceuticals (ATNM) stock price today with other investors in the Actinium Pharmaceuticals NYSE share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NYSE:ATNM share price (ISIN: US00507W2061) to enhance your trading decisions with our free investment tools and resources.
What Is the Actinium Pharmaceuticals Inc Share Price Today?
The Actinium Pharmaceuticals share price today is 1.200.
What Is the Stock Symbol for Actinium Pharmaceuticals Inc
The stock symbol (or 'ticker') for Actinium Pharmaceuticals Inc is "ATNM."
What Stock Exchange Does Actinium Pharmaceuticals Inc Trade On?
Actinium Pharmaceuticals Inc is listed and trades on the NYSE stock exchange.
Is Actinium Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Actinium Pharmaceuticals (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Use the dropdown to select a relevant stock exchange for the current NYSE:ATNM share price (ISIN: US00507W2061) to enhance your trading decisions with our free investment tools and resources.
What Is the Actinium Pharmaceuticals Inc Share Price Today?
The Actinium Pharmaceuticals share price today is 1.200.
What Is the Stock Symbol for Actinium Pharmaceuticals Inc
The stock symbol (or 'ticker') for Actinium Pharmaceuticals Inc is "ATNM."
What Stock Exchange Does Actinium Pharmaceuticals Inc Trade On?
Actinium Pharmaceuticals Inc is listed and trades on the NYSE stock exchange.
Is Actinium Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Actinium Pharmaceuticals (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.180
1.205
52 wk Range
0.735
1.740
ATNM is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.1801.205
52 wk Range
0.7351.740
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ATNM Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
3.600
Upside
+200.00%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to grow this year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Buy
Analyst Ratings
3 Buy
1 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 3.600
(+200.00% Upside)
Earnings
Latest Release
03/08/2026
EPS / Forecast
0.89 / -0.21
Revenue / Forecast
35M / --
Compare ATNM to Peers and Sector
Metrics to compare | ATNM | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipATNMPeersSector | |
|---|---|---|---|---|
P/E Ratio | 3.3x | −6.2x | −0.4x | |
PEG Ratio | 0.03 | 0.27 | 0.00 | |
Price/Book | 1.2x | 2.4x | 2.6x | |
Price / LTM Sales | 1.1x | 4.1x | 3.1x | |
Upside (Analyst Target) | 200.0% | 95.2% | 57.4% | |
Fair Value Upside | Unlock | 2.0% | 7.7% | Unlock |
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a antibody radioconjugate that deliver alpha-emitter Ac-225 to prostate cancer cells. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia. Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company is based in New York, New York.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Actinium Pharmaceuticals (NYSE: ATNM) Share Price Today?
The Actinium Pharmaceuticals stock price today is 1.200 USD.
What Stock Exchange Does Actinium Pharmaceuticals (ATNM) Trade On?
Actinium Pharmaceuticals is listed and trades on the New York Stock Exchange.
What Is the Ticker (Stock Symbol) for Actinium Pharmaceuticals?
The stock symbol (also called a 'ticker') for Actinium Pharmaceuticals is "ATNM."
What Is the Current Actinium Pharmaceuticals Market Capitalisation?
As of today, Actinium Pharmaceuticals (NYSE: ATNM) market cap is 37.730M USD.
What Is Actinium Pharmaceuticals's (ATNM) Earnings Per Share (TTM)?
The Actinium Pharmaceuticals EPS is currently 0.356 (Trailing Twelve Months).
When Is the Next Actinium Pharmaceuticals Earnings Date?
Actinium Pharmaceuticals's next earnings report will be released on 23/11/2026.
Is ATNM a Buy or Sell From a Technical Analyst Perspective?
Based on today's Actinium Pharmaceuticals moving averages and other technical indicators, the daily buy/sell signal for ATNM stock is Strong Buy.
How Many Times Has Actinium Pharmaceuticals Stock Split?
Actinium Pharmaceuticals has split 1 times. (See the ATNM stock split history page for full effective split date and price information.)
How Many Employees Does Actinium Pharmaceuticals Have?
Actinium Pharmaceuticals has 27 employees, based on their latest Companies House report.
What is the current trading status of Actinium Pharmaceuticals (NYSE: ATNM)?
As of 28/09/2026, Actinium Pharmaceuticals (ATNM) is trading at a share price of 1.200 USD, with a previous close of 1.200 USD. The stock has fluctuated within a day range of 1.180 USD to 1.205 USD, while its 52-week range spans from 0.735 USD to 1.740 USD.
What Is Actinium Pharmaceuticals (ATNM) Price Target According to Analysts?
The average 12-month price target for Actinium Pharmaceuticals is 3.600 USD, with a high estimate of 5 USD and a low estimate of 2 USD. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +200.00% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.